Medical Scientist Training Program, at National Institutes of Health (NIH) and his dissertation on tumor immunology.
[3] Later, Gulley did his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship at the NCI.
His studies involved the use of cancer vaccine[5] and immune checkpoint inhibitors or other strategies to enhance vaccine-mediated killing.
[11][12] Some of his notable publications are listed below: At the 2010 ASCO meeting Gulley and his group reported on the use of Ipilimumab with a vector-based vaccine for treating advanced prostate cancer.
This phase I trial using PSA-TRICOM with Ipilimumab (Ipi) showed promise for Overall Survival (OS).